Exogenous introduction of an immunodominant peptide from the non-structural IE1 protein of human cytomegalovirus into the MHC class I presentation pathway by recombinant dense bodies
Exogenous introduction of particle-associated proteins of human cytomegalovirus (HCMV) into the major histocompatibility complex (MHC) class I presentation pathway by subviral dense bodies (DB) is an effective way to sensitize cells against CD8 T-cell (CTL) recognition and killing. Consequently, these particles have been proposed as a platform for vaccine development. We have developed a strategy to refine the antigenic composition of DB. For proof of principle, an HCMV recombinant (RV-VM3) was generated that encoded the immunodominant CTL determinant IE1TMY from the IE1 protein in fusion with the major constituent of DB, the tegument protein pp65. To generate RV-VM3, a bacterial artificial chromosome containing the HCMV genome was modified by applying positive/negative selection based on the expression of the bacterial galactokinase in conjunction with λ Red-mediated homologous recombination. This method allowed the efficient and seamless insertion of the DNA sequence encoding IE1TMY in frame into the pp65 open reading frame (UL83) of the viral genome. RV-VM3 expressed its fusion protein to high levels. The fusion protein was packaged into DB and into virions. Its delivery into fibroblasts by these viral particles led to the loading of the MHC class I presentation pathway with IE1TMY and to efficient killing by specific CTLs. This demonstrated that a heterologous peptide, not naturally present in HCMV particles, can be processed from a recombinant, DB-derived protein to be subsequently presented by MHC class I. The results presented here provide a rationale for the optimization of a vaccine based on recombinant DB.
AndreoniM.,
FairclothM.,
VuglerL.,
BrittW. J.1989; A rapid microneutralization assay for the measurement of neutralizing antibody reactive with human cytomegalovirus. J Virol Methods 23:157–167[CrossRef]
BeningaJ.,
KropffB.,
MachM.1995; Comparative analysis of fourteen individual human cytomegalovirus proteins for helper T cell response. J Gen Virol 76:153–160[CrossRef]
BesoldK.,
FrankenbergN.,
Pepperl-KlindworthS.,
KuballJ.,
TheobaldM.,
HahnG.,
PlachterB.2007; Processing and MHC class I presentation of human cytomegalovirus pp65-derived peptides persist despite gpUS2–11-mediated immune evasion. J Gen Virol 88:1429–1439[CrossRef]
BorstE. M.,
HahnG.,
KoszinowskiU. H.,
MesserleM.1999; Cloning of the human cytomegalovirus (HCMV) genome as an infectious bacterial artificial chromosome in Escherichia coli : a new approach for construction of HCMV mutants. J Virol 73:8320–8329
BorysiewiczL. K.,
HicklingJ. K.,
GrahamS.,
SinclairJ.,
CranageM. P.,
SmithG. L.,
SissonsJ. G.1988; Human cytomegalovirus-specific cytotoxic T cells. Relative frequency of stage-specific CTL recognizing the 72-kD immediate early protein and glycoprotein B expressed by recombinant vaccinia viruses. J Exp Med 168:919–931[CrossRef]
BundeT.,
KirchnerA.,
HoffmeisterB.,
HabedankD.,
HetzerR.,
CherepnevG.,
ProeschS.,
ReinkeP.,
VolkH. D.other authors2005; Protection from cytomegalovirus after transplantation is correlated with immediate early 1-specific CD8 T cells. J Exp Med 201:1031–1036[CrossRef]
Chee, M. S., Bankier, A. T., Beck, S., Bohni, R., Brown, C. M., Cerny, R., Horsnell, T., Hutchison, C. A., 3rd, Kouzarides, T. & other authors 1990; Analysis of the protein-coding content of the sequence of human cytomegalovirus strain AD169. Curr Top Microbiol Immunol 154:125–169
CraigheadJ. E.,
KanichR. E.,
AlmeidaJ. D.1972; Nonviral microbodies with viral antigenicity produced in cytomegalovirus-infected cells. J Virol 10:766–775
DavignonJ. L.,
CastanieP.,
YorkeJ. A.,
GautierN.,
ClementD.,
DavrincheC.1996; Anti-human cytomegalovirus activity of cytokines produced by CD4+ T-cell clones specifically activated by IE1 peptides in vitro. J Virol 70:2162–2169
DiamondD. J.,
YorkJ.,
SunJ. Y.,
WrightC. L.,
FormanS. J.1997; Development of a candidate HLA A*0201 restricted peptide-based vaccine against human cytomegalovirus infection. Blood 90:1751–1767
ElkingtonR.,
WalkerS.,
CroughT.,
MenziesM.,
TellamJ.,
BharadwajM.,
KhannaR.2003; Ex vivo profiling of CD8+-T-cell responses to human cytomegalovirus reveals broad and multispecific reactivities in healthy virus carriers. J Virol 77:5226–5240[CrossRef]
FalkC. S.,
MachM.,
SchendelD. J.,
WeissE. H.,
HilgertI.,
HahnG.2002; NK cell activity during human cytomegalovirus infection is dominated by US2-11-mediated HLA class I down-regulation. J Immunol 169:3257–3266[CrossRef]
FrankenbergN.,
Pepperl-KlindworthS.,
MeyerR. G.,
PlachterB.2002; Identification of a conserved HLA-A2-restricted decapeptide from the IE1 protein (pUL123) of human cytomegalovirus. Virology 295:208–216[CrossRef]
Gallez-HawkinsG.,
VillacresM. C.,
LiX.,
SanbornM. C.,
LomeliN. A.,
ZaiaJ. A.2003; Use of transgenic HLA A*0201/Kb and HHD II mice to evaluate frequency of cytomegalovirus IE1-derived peptide usage in eliciting human CD8 cytokine response. J Virol 77:4457–4462[CrossRef]
HobomU.,
BruneW.,
MesserleM.,
HahnG.,
KoszinowskiU. H.2000; Fast screening procedures for random transposon libraries of cloned herpesvirus genomes: mutational analysis of human cytomegalovirus envelope glycoprotein genes. J Virol 74:7720–7729[CrossRef]
IrmiereA.,
GibsonW.1983; Isolation and characterization of a noninfectious virion-like particle released from cells infected with human strains of cytomegalovirus. Virology 130:118–133[CrossRef]
KernF.,
SurelI. P.,
FaulhaberN.,
FrömmelC.,
Schneider-MergenerJ.,
SchonemannC.,
ReinkeP.,
VolkH. D.1999; Target structures of the CD8+-T-cell response to human cytomegalovirus: the 72-kilodalton major immediate-early protein revisited. J Virol 73:8179–8184
KhanN.,
BrutonR.,
TaylorG. S.,
CobboldM.,
JonesT. R.,
RickinsonA. B.,
MossP. A.2005; Identification of cytomegalovirus-specific cytotoxic T lymphocytes in vitro is greatly enhanced by the use of recombinant virus lacking the US2 to US11 region or modified vaccinia virus Ankara expressing individual viral genes. J Virol 79:2869–2879[CrossRef]
ManleyT. J.,
LuyL.,
JonesT.,
BoeckhM.,
MutimerH.,
RiddellS. R.2004; Immune evasion proteins of human cytomegalovirus do not prevent a diverse CD8+ cytotoxic T-cell response in natural infection. Blood 104:1075–1082[CrossRef]
McLaughlin-TaylorE.,
PandeH.,
FormanS. J.,
TanamachiB.,
LiC. R.,
ZaiaJ. A.,
GreenbergP. D.,
RiddellS. R.1994; Identification of the major late human cytomegalovirus matrix protein pp65 as a target antigen for CD8+ virus-specific cytotoxic T lymphocytes. J Med Virol 43:103–110[CrossRef]
MesserleM.,
CrnkovicI.,
HammerschmidtW.,
ZieglerH.,
KoszinowskiU. H.1997; Cloning and mutagenesis of a herpesvirus genome as an infectious bacterial artificial chromosome. Proc Natl Acad Sci U S A 94:14759–14763[CrossRef]
PassR. F.2001; Cytomegalovirus. In Fields Virology . , 4th edn. pp 2675–2705Edited byKnipeD. M.,
HowleyP. M.
Philadelphia, PA: Lippincott Williams and Wilkins;
PepperlS.,
MünsterJ.,
MachM.,
HarrisJ. R.,
PlachterB.2000; Dense bodies of human cytomegalovirus induce both humoral and cellular immune responses in the absence of viral gene expression. J Virol 74:6132–6146[CrossRef]
Pepperl-KlindworthS.,
PlachterB.2006; Current perspectives in vaccine development. In Cytomegaloviruses: Molecular Biology and Immunology Edited by ReddehaseM. J.
Wymondham, UK: Caister Academic Press;
Pepperl-KlindworthS.,
FrankenbergN.,
PlachterB.2002; Development of novel vaccine strategies against human cytomegalovirus infection based on subviral particles. J Clin Virol 25:Suppl. 2S75–S85[CrossRef]
Pepperl-KlindworthS.,
FrankenbergN.,
RieglerS.,
PlachterB.2003; Protein delivery by subviral particles of human cytomegalovirus. Gene Ther 10:278–284[CrossRef]
PlachterB.,
BrittW. J.,
VornhagenR.,
StammingerT.,
JahnG.1993; Analysis of proteins encoded by IE-regions 1 and 2 of human cytomegalovirus using monoclonal antibodies generated against recombinant antigens. Virology 193:642–652[CrossRef]
ReddehaseM. J.,
KeilG. M.,
KoszinowskiU. H.1984; The cytolytic T lymphocyte response to the murine cytomegalovirus. II. Detection of virus replication stage-specific antigens by separate populations of in vivo active cytolytic T lymphocyte precursors. Eur J Immunol 14:56–61[CrossRef]
RiddellS. R.,
RabinM.,
GeballeA. P.,
BrittW. J.,
GreenbergP. D.1991; Class I MHC-restricted cytotoxic T lymphocyte recognition of cells infected with human cytomegalovirus does not require endogenous viral gene expression. J Immunol 146:2795–2804
SchmolkeS.,
KernH. F.,
DrescherP.,
JahnG.,
PlachterB.1995; The dominant phosphoprotein pp65 (UL83) of human cytomegalovirus is dispensable for growth in cell culture. J Virol 69:5959–5968
SeveriB.,
LandiniM. P.,
GovoniE.1988; Human cytomegalovirus morphogenesis: an ultrastructural study of the late cytoplasmic phases. Arch Virol 98:51–64[CrossRef]
SimonC. O.,
HoltappelsR.,
TervoH. M.,
BöhmV.,
DäubnerT.,
Oehrlein-KarpiS. A.,
KühnapfelB.,
RenzahoA.,
StrandD.other authors2006; CD8 T cells control cytomegalovirus latency by epitope-specific sensing of transcriptional reactivation. J Virol 80:10436–10456[CrossRef]
SylwesterA. W.,
MitchellB. L.,
EdgarJ. B.,
TaorminaC.,
PelteC.,
RuchtiF.,
SleathP. R.,
GrabsteinK. H.,
HoskenN. A.other authors2005; Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects. J Exp Med 202:673–685[CrossRef]
TopilkoA.,
MichelsonS.1994; Morphological and cytochemical analysis of human cytomegalvirus inoculum: correlation of free particles in inoculum with counterparts in infected cells. Res Virol 145:65–73[CrossRef]
VarnumS. M.,
StreblowD. N.,
MonroeM. E.,
SmithP.,
AuberryK. J.,
Pasa-TolicL.,
WangD.,
CampD. G.,
RodlandK.other authors2004; Identification of proteins in human cytomegalovirus (HCMV) particles: the HCMV proteome. J Virol 78:10960–10966[CrossRef]
Vaz-SantiagoJ.,
LuleJ.,
RohrlichP.,
JacquierC.,
GibertN.,
LeR. E.,
BetbederD.,
DavignonJ. L.,
DavrincheC.2001; Ex vivo stimulation and expansion of both CD4+ and CD8+ T cells from peripheral blood mononuclear cells of human cytomegalovirus-seropositive blood donors by using a soluble recombinant chimeric protein, IE1-pp65. J Virol 75:7840–7847[CrossRef]
WillsM. R.,
CarmichaelA. J.,
MynardK.,
JinX.,
WeekesM. P.,
PlachterB.,
SissonsJ. G.1996; The human cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp65: frequency, specificity, and T-cell receptor usage of pp65- specific CTL. J Virol 70:7569–7579
Exogenous introduction of an immunodominant peptide from the non-structural IE1 protein of human cytomegalovirus into the MHC class I presentation pathway by recombinant dense bodies